Friday, December 1, 2023
Clinical Advances in
As research advances, we continue to expand our knowledge and understanding of novel targets in DNA damage response as potential therapeutic options in oncology. While PARP inhibitors have led the way, and are increasingly being recognized as a targeted therapeutic approach for patients with BRCA mutations and other indicators of susceptibility, agents targeting different DNA damage response pathways may potentially reshape the treatment landscape in oncology in the near future.
This curriculum explores the recent clinical advances with agents targeting different aspects of DNA damage response, their rationale for use, and emerging clinical data.
Supported by an independent educational grant from
Steering Committee Chair
Professor, Experimental Cancer Medicine; Head, Clinical Studies Division; Director, Drug Development Unit; Head, Prostate Cancer Targeted Therapy Group; Honorary Consultant, Medical Oncology, The Institute of Cancer Research/Royal Marsden NHS Foundation Trust, Sutton, Surrey, England, United Kingdom
Professor, University of Milan-Bicocca; Director, Gynecologic Oncology Program, European Institute of Oncology, Milan, Italy
Head, Breast Cancer and Gynecological Tumours, Oncology Department, Ramón y Cajal University Hospital, Madrid, Spain; Clinical Investigator, Breast Cancer Research Program, Vall d'Hebron Institute of Oncology, Barcelona, Spain
Professor of Medicine, University of British Columbia; Medical Oncologist, BC Cancer Agency, Vancouver, British Columbia, Canada
Professor; Chair, Medical Oncology; Honorary Consultant, Medical Oncology; Director, Nicola Murray Centre for Ovarian Cancer Research, Edinburgh Cancer Research Centre, The University of Edinburgh, Edinburgh, Scotland, United Kingdom
Steering Committee Chair
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Astellas Pharma, Inc.; Daichi Sankyo, Inc.; Genentech, Inc.; GlaxoSmithKline; Janssen Pharmaceuticals; Sanofi; Taiho
Received grants for clinical research from: AstraZeneca; Daichi; Genentech; Janssen; Sanofi; Taiho Pharmaceutical Co., Ltd.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Clovis Oncology; Pfizer Inc.; PharmaMar; Roche; TESARO, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; PharmaMar; Roche; TESARO, Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Biothera Pharmaceuticals; Celgene Corporation; Cellestia Biotech; Merus; Roche
Served as a speaker or a member of a speakers bureau for: Celgene Corporation; Eisai Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Roche
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Bristol-Myers Squibb Company; Genentech, Inc.; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Pfizer Inc.
Has disclosed the following relevant financial relationships
Served as an advisor or consultant for: AstraZeneca Pharmaceuticals LP; Foundation One; Roche; TESARO, Inc.
Served as a speaker or a member of a speakers bureau for: AstraZeneca Pharmaceuticals LP; TESARO, Inc.
Received grants for clinical research from: Aprea; AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation; Nucana; TESARO, Inc.